Consistent with the roles of OX40 and PD-1 in memory T-cell formation [23], [43], individual PD-1 blockade or OX40 triggering modestly increased the percentage of CD44+CD62L− effector/memory and/or CD44+CD62L+ central memory T cells; importantly, combined anti-PD-1/OX40 mAb synergistically promoted the development of effector/memory and central memory T cells in peritoneal cavity, which constitutes the basis for the resistance of long-term surviving mice from 2 mAb treated group to the same tumor rechallenge. The gene discussed is CD44; the disease is neoplasm.